Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:236 (28 January), doi:10.1136/bmj.332.7535.236-b
EditorGastro-oesophageal reflux disease, being increasingly common, is a huge problem, and prescribing of proton pump inhibitors is a large burden on the NHS. Fox and Forgacs mentioned surgical management towards the end of their article,1 but we disagree with the implication that antireflux surgery is limited to those patients in whom medical management is either ineffective or poorly tolerated. For patients who do not want to remain dependent on daily drug treatment it may simply be an alternative treatment, a lifestyle choice.
Also not mentioned was our recent randomised controlled trial of laparoscopic Nissen fundoplication v proton pump inhibitors, carried out in the United Kingdom.2 This gave results favouring surgical fundoplication. It was accompanied by our economic analysis,3 which shows that surgical management, in the long term, is the more cost effective solution. This is an important consideration in today's NHS.
David Mahon, specialist registrar general surgery
North Hampshire Hospitals NHS Trust, Basingstoke RG24 9NA bmj{at}amigo.co.uk
Michael Rhodes, consultant surgeon
Norfolk and Norwich University Hospital, Norwich NR4 7UY